Clifford Bechtold
Compliance Officer at BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
Profile
Mr. Clifford Bechtold is a Chief Operating Officer at Biohaven Pharmaceutical Holding Co. Ltd. Mr. Bechtold was previously employed as a Vice President-Strategic Operations by Adnexus and a Staff Director by Bristol Myers Squibb Co. He received his undergraduate degree from South Dakota State University and a graduate degree from The Creighton University School of Medicine.
Clifford Bechtold active positions
Companies | Position | Start |
---|---|---|
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Compliance Officer | - |
BIOHAVEN LTD. | Compliance Officer | - |
Former positions of Clifford Bechtold
Companies | Position | End |
---|---|---|
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 2013-10-31 |
Adnexus
Adnexus Pharmaceuticals: MajorHealth Technology Adnexus engages in the development of Adnectins biologics and medicines in the United States. The company was founded by Frank D. Lee on September 16, 2002 and is headquartered in Waltham, MA. | Corporate Officer/Principal | 2011-09-30 |
Training of Clifford Bechtold
South Dakota State University | Undergraduate Degree |
The Creighton University School of Medicine | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
BIOHAVEN LTD. | Health Technology |
Private companies | 2 |
---|---|
Adnexus
Adnexus Pharmaceuticals: MajorHealth Technology Adnexus engages in the development of Adnectins biologics and medicines in the United States. The company was founded by Frank D. Lee on September 16, 2002 and is headquartered in Waltham, MA. | Health Technology |
Biohaven Pharmaceutical Holding Co. Ltd.
Biohaven Pharmaceutical Holding Co. Ltd. Pharmaceuticals: MajorHealth Technology Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT. | Health Technology |
- Stock Market
- Insiders
- Clifford Bechtold